Ectopic Overexpression of PPARγ2 in the Heart Determines Differences in Hypertrophic Cardiomyopathy After Treatment With Different Thiazolidinediones in a Mouse Model of Diabetes

The clinical controversy of rosiglitazone as a hypoglycemic agent is potentially associated with heart failure, mainly due to its potent activation of peroxisome proliferator-activated receptor γ (PPARγ). PPARγ partial agonists showed superior pharmacological profiles to rosiglitazone. This study co...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Xuemei, Mao, Min, Diao, Junlin, Hou, Yi, Su, Hong, Gan, Yongjun, Li, Jibin, Tong, Xiaoyong, Wu, Chaodong, Zuo, Zhong, Xiao, Xiaoqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293689/
https://www.ncbi.nlm.nih.gov/pubmed/34305596
http://dx.doi.org/10.3389/fphar.2021.683156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293689/
https://www.ncbi.nlm.nih.gov/pubmed/34305596
http://dx.doi.org/10.3389/fphar.2021.683156

Ejemplares similares